Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries

English version České info

Background:
Certain non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., rofecoxib [Vioxx]) increase the risk of heart attack and stroke and should be avoided in patients at high risk of cardiovascular events. Rates of cardiovascular disease are high and rising in many low- and middle-income countries. We studied the extent to which evidence on cardiovascular risk with NSAIDs has translated into guidance and sales in 15 countries.

Methods and Findings:
Data on the relative risk (RR) of cardiovascular events with individual NSAIDs were derived from meta-analyses of randomised trials and controlled observational studies. Listing of individual NSAIDs on Essential Medicines Lists (EMLs) was obtained from the World Health Organization. NSAID sales or prescription data for 15 low-, middle-, and high-income countries were obtained from Intercontinental Medical Statistics Health (IMS Health) or national prescription pricing audit (in the case of England and Canada). Three drugs (rofecoxib, diclofenac, etoricoxib) ranked consistently highest in terms of cardiovascular risk compared with nonuse. Naproxen was associated with a low risk. Diclofenac was listed on 74 national EMLs, naproxen on just 27. Rofecoxib use was not documented in any country. Diclofenac and etoricoxib accounted for one-third of total NSAID usage across the 15 countries (median 33.2%, range 14.7–58.7%). This proportion did not vary between low- and high-income countries. Diclofenac was by far the most commonly used NSAID, with a market share close to that of the next three most popular drugs combined. Naproxen had an average market share of less than 10%.

Conclusions:
Listing of NSAIDs on national EMLs should take account of cardiovascular risk, with preference given to low risk drugs. Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity. Diclofenac should be removed from EMLs.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. PLoS Med 10(2): e32767. doi:10.1371/journal.pmed.1001388
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001388

Souhrn

Zdroje

1. GrosserT, FriesS, FitzGeraldGA (2006) Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4–15.

2. HenryD, LimL, Garcia RodriguezL, Perez GutthannS, CarsonJL, et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312: 1563–1566.

3. Masso GonzalezE, PatrignaniP, TacconelliS, Garcia RodriguezL (2010) Variability among non-steroidal anti-inflammatory drugs in risk of upper gastrointestinal bleeding. Arth Rheum 62: 1592–1601.

4. Hernandez-DıazS, Varas-Lorenzo, Garcıa RodrıguezL (2006) Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98: 266–274.

5. SinghS, WuO, LanghorneP, MadhokR (2006) Risk of acute myocardial infarction with non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 8: R153.

6. McGettiganP, HenryD (2006) Cardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective anad non-selective inhibitors of cyclo-oxygenase. JAMA 296: 1633–1644.

7. TrelleS, ReichenbachS, WandelS, HildebrandP, TschannenB, et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: a network meta-analysis. BMJ 342: c7086.

8. KearneyP, BaigentC, GoodwinJ, HallsH, EmbersonJ, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308.

9. McGettiganP, HenryD (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8: e1001098 doi:10.1371/journal.pmed.1001098.

10. ScheimanJM, HindleyCE (2010) Strategies to optimise treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 32: 667–677.

11. RostomA, MuirK, DubeC, LanasA, JolicoeurE, TugwellP (2009) Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and cox-2 inhibitors. Drug Healthcare Patient Safety 1: 47–71.

12. StrandV (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370: 2138–51.

13. Garcia RodriguezL, TacconelliS, PatrignaniP (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52: 1628–1636.

14. DansA, NgN, VargheseC, TaiES, FirestoneR, et al. (2011) The rise of chronic non-communicable diseases in Southeast Asia: time for action. Lancet 337: 680–89.

15. World Health Organization (2011) WHO model list of essential medicines 17th List March 2011. Available: http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf. Accessed 12 September 2012.

16. World Health Organization (2012) Essential medicines selection. Available: http://www.who.int/selection_medicines/country_lists/en/index.html. Accessed 12 September 2012.

17. World Health Organization (2010) Fact sheet number 325. Medicines: essential medicines. Available: http://www.who.int/mediacentre/factsheets/fs325/en/index.html. Accessed 4 November 2012.

18. World Health Organization (2012) ATC/DDD Index 2012. Available: http://www.whocc.no/atc_ddd_index/. Accessed 12 September 2012.

19. NHS (2011) Prescription cost analysis England 2011. Available: http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england-2011. Accessed 12 November 2012.

20. Merck (2004) Merck announces voluntary worldwide withdrawal of Vioxx. Available: http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf. Accessed 12 September 2012.

21. FosbolEL, FolkeF, JacobsenS, RasmussenJN, SørensenR, et al. (2010) Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 3: 395–405.

22. CannonCP, CurtisSP, FitzGeraldGA, KrumH, KaurA, BologneseJA, et al. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781.

23. World Health Organization (2012) NCD mortality 2008. Available: http://gamapserver.who.int/gho/interactive_charts/ncd/mortality/cvd/atlas.html. Accessed 12 September 2012.

24. DeeksJJ, SmithLA, BradleyMD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for the treatment of osteoarthritis and rheumatoid arthritis: a systematic review of randomised controlled trials. BMJ 325: 619–623.

25. CollinsSL, MooreRA, McQuayHJ, WiffenPJ (1998) Oral ibuprofen and diclofenac in post-operative pain: a quantitative systematic review. Eur J Pain 2: 285–291.

26. European Medicines Agency (2012) Questions and answers on the review of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk: outcome of a procedure under Article 5(3) of Regulation (EC) No 726/20041. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001637.jsp&mid=WC0b01ac058004d5c1. Accessed 11 November 2012.